Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin

Mayo Clinic Proceedings

Volumn 85, Issue 2, 2010, Pages 122-128

  Bays, Harold E ^a   McKenney, James ^b   Maki, Kevin C ^c   Doyle, Ralph T ^d,e   Carter, Roderick N ^d,e   Stein, Evan ^f  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b National Clinical Research Inc   (United States)

^c Provident Clinical Research and Consulting Inc   (United States)

^d Reliant Pharmaceuticals Inc   (United States)

^e WellGen Inc   (United States)

^f Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BIOLOGICAL MARKER; CHOLESTEROL; CREATINE KINASE; FISH OIL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 75749115919     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0397     Document Type: Article

References (27)

1. Bays HE, McKenney J, Doyle RT, Carter RN, Stein E. Effect of prescription omega-3 fatty acids coadministered with escalating doses of atorvastatin in patients with hypertriglyceridemia [abstract 5150]. Circulation. 2008;118:S1152.
2. Bays HE, McKenney J, Doyle RT, Carter RN, Stein E. Prescription omega-3s coadministered with atorvastatin for patients with hypertriglyceridemia. Encore poster presented at: American Association of Diabetes Educators 2009 Annual Meeting; August 5-8, 2009, Atlanta, GA.
3. Bays HE, McKenney J, Doyle RT, Carter RN, Stein E. Effect of prescription omega-3 fatty acids coadministered with escalating doses of atorvastatin on non-HDL-C in patients with hypertriglyceridemia. Encore poster presented at: American College of Clinical Pharmacy Annual Meeting 2009, Anaheim, CA, October 18-21, 2009.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
5. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15):1512-1524.
6. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391-409.
7. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS). Circulation. 2000;101(5):477-484.
8. Kastelein JJ, van der Steeg WA, Holme I, et al; TNT Study Group; IDEAL Study Group. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117(23):3002-3009.
9. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53(4):316-322.
10. U. S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Your Guide to Lowering Cholesterol With TLC: Therapeutic Lifestyle Changes. Bethesda, MD: National Institute of Health Publication No. 06-5235; December 2005. http://www.nhlbi. nih.gov/health/public/heart/chol/chol-tlc.pdf. Accessed November 6, 2009.
11. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96(4):556-563.
12. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebocontrolled study. Clin Ther. 2007;29(7):1354-1367.
13. Nordøy A, Bønaa KH, Nilsen H, Berge RK, Hansen JB, Ingebretsen OC. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med. 1998;243(2):163-170.
14. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001;85(5):544-548.
15. Chan DC, Watts GF, Nguyen MN, Barrett PH. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr. 2006;84(1):37-43.
16. Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia [published correction appears in am J Cardiol. 2008;102(10):1425]. Am J Cardiol. 2008;102(4):429-433.
17. Hartweg J, Farmer AJ, Holman RR, Neil A. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr Opin Lipidol. 2009;20(1):30-38.
18. Balk E, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evidence report/technology assessment no 93 (Prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022). AHRQ publication no 04-E010-2. Rockville, Md: Agency for Healthcare Research and Quality; 2004. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book= hserta&part=A136037. Accessed November 6, 2009.
19. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391-409.
20. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98(4A):27i-33i.
21. Khan S, Minihane AM, Talmud PJ, et al. Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res. 2002;43(6):979-985.
22. Davidson MH, Maki KC, Bays HE, Bays H, Carter R, Ballantyne CM. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2009;3(5):442-340.
23. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17(4):387-393.
24. Zaima N, Sugawara T, Goto D, Hirata T. Trans geometric isomers of EPA decrease LXRα-induced cellular triacylglycerol via suppression of SREBP-1c and PGC-1β. J Lipid Res. 2006;47(12):2712-2717.
25. Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol. 2006;97(8A):6C-26C.
26. Isaacsohn J, Hunninghake D, Schrott H, et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003;26(1):18-24.
27. Bays H. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians. Drugs Today (Barc). 2008;44(3):205-246.